Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017 Summary Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2017, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Toxicology which include indications Osteoarthritis Pain, Alzheimer's Disease, Cancer Pain, Low Back Pain, Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Diabetic Neuropathy, Huntington Disease, Interstitial Cystitis (Painful Bladder Syndrome), Keratitis, Mild Cognitive Impairment, Optic Nerve Injury, Peripheral Nerve Injury and Post-Operative Pain. Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF) - The report reviews Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects - The report assesses Beta Nerve Growth Factor (Beta NGF or NGF)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Beta Nerve Growth Factor (Beta NGF or NGF) - Overview Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development Amgen Inc Astellas Pharma Inc Fujimoto Pharmaceutical Corp Krenitsky Pharmaceuticals Inc MedImmune LLC NsGene A/S Pfizer Inc Regeneron Pharmaceuticals Inc Serometrix LLC Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles AS-288640100 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-6294 - Drug Profile Product Description Mechanism Of Action R&D Progress fasinumab - Drug Profile Product Description Mechanism Of Action R&D Progress fulranumab - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate NGF for Optic Nerve Injury - Drug Profile Product Description Mechanism Of Action R&D Progress KP-544 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-7352 - Drug Profile Product Description Mechanism Of Action R&D Progress NsG-0202 - Drug Profile Product Description Mechanism Of Action R&D Progress RBM-004 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Neurotrophic Keratitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit NGF for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress tanezumab - Drug Profile Product Description Mechanism Of Action R&D Progress Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones Featured News & Press Releases Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab May 12, 2010: Regeneron Provides Initial Data On REGN475 Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010 Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202 Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer's Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by Fujimoto Pharmaceutical Corp, H1 2017 Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017 Pipeline by MedImmune LLC, H1 2017 Pipeline by NsGene A/S, H1 2017 Pipeline by Pfizer Inc, H1 2017 Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Pipeline by Serometrix LLC, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
